PDS Biotechnology Corporation (PDSB): Price-to-Projected Revenue Ratio

PDSB (PDS Biotechnology Corp) - company brandmark

PDS Biotechnology is developing unique Versamune vaccines with the potential for monopoly pricing power. The forward price-to-sales valuation trend, based on GURU.Markets data, confirms this trajectory, while captures the current state of the parameter. Success is driven by transparent capital management and a strategy of forming strategic alliances with pharma behemoths for joint molecule trials.

PDSB PDS Biotechnology Corp: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for pdsbiotech.com (PDSB)

- stock price and consensus target price:
Stock Quotes PDS Biotechnology Corporation|PDSB - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value PDS Biotechnology Corporation|PDSB - Business Value
- book value of equity indicators:
Net Assets per Single Share PDS Biotechnology|PDSB - Total Stockholders' Equity|Market Cap to Net Assets Ratio pdsbiotech.com|PDSB - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio PDS Biotechnology|PDSB - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital PDS Biotechnology Corporation|PDSB - Aggregate Debt Obligations|Debts to Book Capitalization PDS Biotechnology Corporation|PDSB - Long-Term Debt|Company Short-Term Debt PDS Biotechnology|Quick Ratio pdsbiotech.com
- business earnings and investment ratios data:
PDSB - Net Profit|Expected Profit PDS Biotechnology|PDSB - Market Cap to Net Income|Projected Price to Earnings PDS Biotechnology Corporation|PDSB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PDS Biotechnology Corporation|PDSB - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) PDS Biotechnology|PDSB - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months pdsbiotech.com|PDSB - Expected net earnings per share growth this year|Expected earnings per share growth for next year PDS Biotechnology
- revenue and sales details:
PDSB - Company Sales Revenue|Projected Sales Volume PDS Biotechnology Corporation|PDSB - Price-to-Revenue Ratio|Forward P/S Multiple PDS Biotechnology Corporation
Summary company analysis:PDS Biotechnology Corp PDSB
Manufactured products of pdsbiotech.com

Investors must determine whether the current valuation of PDS Biotechnology (PDSB) is justified or reflects a systemic business decline. Analyzing the company's forward P/S chart, which compares market capitalization against expected sales volume, reveals a potential "value trap" risk, which is critical for PDS Biotechnology (PDSB) given its dependence on clinical trial outcomes and the capital shortfall prior to vaccine commercialization.

Competitor analysis

ImmunityBio - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Holdings IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (Arcus Corp) - Market Cap to Projected Revenue|Zymeworks Inc. (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio tangotx.com (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune Group, Inc.)|Forward Price to Sales LYEL|Innate Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology, Inc.|cgen.com (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech Inc. - Forward Price to Sales|STRO (Sutro Biopharma, Inc.) - Forward P/S Multiple|Forward P/S Multiple minktherapeutics.com|Price-to-Projected Revenue Ratio Werewolf Therapeutics (HOWL)|IMMX: Future Price to Revenue|ALX Oncology Holdings - Forward Price-to-Revenue Multiple|cuebiopharma.com (CUE) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|Future Price to Revenue MAIA|LIMN: Forward P/S Multiple|Market Cap to Projected Revenue LVTX|Price-to-Projected Revenue Ratio NextCure Corp|Leap Tx (LPTX) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple INTS (Intensity Therapeutics)|SNSE (senseibio.com) - Forward Price to Sales|Forward P/S Multiple TOVX (Theriva Biologics)|Gritstone bio Inc. - Price-to-Projected Revenue Ratio|Kineta Bio - Forward P/S Multiple|Market Cap to Expected Sales Ratio NexImmune Corporation NEXI|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio vaccinex.com (VCNX)|Forward Price-to-Revenue Multiple HARP